Researchers pinpoint possible new cause for unexplained miscarriagesNovember 01, 2011
TORONTO, ON., Nov. 1, 2011--Researchers at St. Michael's Hospital have identified a potential new cause for unexplained miscarriages in mice.
They also identified two possible treatments to prevent these miscarriages and their work has broader implications for the development of new drugs to treat heart attacks and strokes.
The researchers, led by Dr. Heyu Ni, found that the same kind of blood-clotting in coronary arteries or blood vessels in the brain that causes heart attacks and strokes also happens in the placenta. The massive clotting can destroy the placenta, block blood flow to the fetus and cause miscarriages.
This condition is known as fetal and neonatal immune thrombocytopenia (FNIT), a bleeding disorder in which mothers generate antibodies that attack and destroy platelets in their fetuses and newborns. Platelets are the small cells in the blood that play a key role in clotting. In severe cases, FNIT may lead to bleeding in the brains of the fetuses and newborns and cause neurological impairment or even death.
The condition affects between one in 800 and one in 1,500 live births and is more commonly reported among Caucasians.
Maternal antibodies to one specific platelet antigen, HPA-1 (human platelet antigen) cause 75-95 per cent of FNIT cases. Antigens are the proteins that antibodies attack because they think they are a foreign substance such as bacteria or a virus.
Dr. Ni and his team discovered a novel mechanism that might partially explain this problem. They found that another antigen, HPA-2, causes a type of FNIT never described before that can lead to miscarriages in more than 83 per cent of mice. There have been only six to eight reported live births in the world of humans with FNIT caused by HPA-2. The new research suggests the reason these cases appear to be so rare is that most of the affected fetuses died through miscarriages, before doctors examined them.
Dr. Conglei Li and other researchers in Dr. Ni's laboratory found that sometimes these antibodies not only destroy platelets, but activate them and cause massive clotting in the placentas.
Dr. Ni, an immunologist, is also a scientist with Canadian Blood Services (CBS), one of the funders of this research. His findings appear in the November issue of the prestigious Journal of Clinical Investigation.
Dr. Ni's group demonstrated that, in mice, these miscarriages can be prevented using at least two therapies. One is the transfusion of IgG (IVIG), a CBS product made from plasma from donated blood, which has been widely used to treat several autoimmune diseases. The other is the transfusion of an antibody known as anti-FcRn, which blocks the attacking maternal antibodies from crossing the placenta. This second method was developed by Dr. Ni's group.
"Fifty per cent of pregnancies do not end in a live birth. Our findings may help explain why some women are having miscarriages," said Dr. Ni. "Furthermore, our treatments could be the answer to carrying a healthy child to term."
The observations by Dr. Ni's team of platelet activation and enhancement of clotting may be important in the development of safer anti-thrombotic drugs. These drugs are under development by several companies.
Dr. Ni's group is now collaborating with clinicians to address how relevant these discoveries in mice are in humans.
St. Michael's Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future health care professionals in more than 23 academic disciplines. Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, and care of the homeless are among the Hospital's recognized areas of expertise. Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Center, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael's Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto.
For more information, please contact:
Manager, Media Strategy,
Phone: 416-864-6094 or 647-300-1753
St. Michael's Hospital
Inspired Care. Inspiring Science.
Follow us on Twitter: http://www.twitter.com/stmikeshospital
St. Michael's Hospital
Related Antibodies Articles:
After analyzing the blood of a survivor of the 2013-16 Ebola outbreak, a team of scientists from academia, industry and the government has discovered the first natural human antibodies that can neutralize and protect animals against all three major disease-causing ebolaviruses.
Researchers from the University of Maryland and Rockefeller University have refined a method to modify an antibody's sugar group structure, which plays a large role in determining an antibody's ability to activate the immune response.
Antibodies are able to activate human nerve cells within milliseconds and hence modify their function -- that is the surprising conclusion of a study carried out at Human Biology at the Technical University of Munich (TUM).
Researchers at the University of California, Riverside have camels and llamas to thank for their development of a new cancer treatment that is highly selective in blocking the action of faulty matrix metalloproteinases (MMPs).
Researchers have identified neutralizing antibodies against Zika virus from an infected patient that fully protected mice from infection, adding to the current arsenal of antibodies in development for much needed antiviral therapies and vaccines.
Spinal cord injury (SCI) causes long-lasting damage in the spinal cord that leads to paraparesis, paraplegia, quadriplegia and other lifetime disabilities.
During HIV infection, the virus mutates too rapidly for the immune system to combat, but some people produce antibodies that can recognize the virus even two years after infection.
Emory scientists probe activated B cells, important for forming immune memory, during flu vaccination and infection and Ebola infection in humans.
Antibodies that specifically protect against Zika infection have been identified in mice, report Washington University School of Medicine in St.
Scientists at Washington University School of Medicine in St. Louis have identified antibodies capable of protecting against Zika virus infection, a significant step toward developing a vaccine, better diagnostic tests and possibly new antibody-based therapies.
Related Antibodies Reading:
Antibodies A Laboratory Manual, Second edition
by Edward A. Greenfield (Editor)
It has been 25 years since the now-classic Antibodies by Ed Harlow and David Lane appeared. While some things remain the same, many have changed. This second edition of Antibodies, edited by Edward A. Greenfield of the Dana-Farber Cancer Institute builds on the core strengths of the first edition, presenting clear and authoritative protocols with extensive background information and troubleshooting advice. The original introductory chapters have been recast and updated to take into account our current understanding of the immune system. The critical chapters on generating monoclonal... View Details
by Antoine Dagata (Author)
This monumental collection of d’Agata’s controversial work is a cult classic and companion to one of the most talked-about photography exhibitions of the past decade, available now for the first time in English. Containing striking images of people living on the fringes of society, Antibodies is a challenging and captivating collection from one of the most renowned photographers working today. Antoine d’Agata has traveled the world’s darkest corners collecting images of prostitutes, addicts, war-torn communities, and the homeless. A nomad himself, d’Agata tackles subjects often left... View Details
Antibodies: A Laboratory Manual
by Ed Harlow (Author), David P Lane (Author)
ince its publication in 1988, Antibodies: A Laboratory Manual, by Harlow and Lane, has become a classic, an essential resource for molecular biology, immunology, and cell culture labs. In order to keep the book in print, Cold Spring Harbor Laboratory Press eventually produced the paperback edition currently available for sale.
Now, after 25 years, a second edition is being published in September 2013. Revised, extended and updated by Edward Greenfield of the Dana-Farber Cancer Center, the material has been recast with extensive new information and new chapters have been added. The new... View Details
Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer
by Kenneth J. Olivier Jr. (Editor), Sara A. Hurvitz (Editor)
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells.
• Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies
• Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging
• Includes case studies of ADCs in oncology drug development
• Features contributions from highly-regarded experts on the... View Details
Monoclonal Antibodies: Meeting the Challenges in Manufacturing, Formulation, Delivery and Stability of Final Drug Product
by Steven Shire (Author)
Monoclonal antibodies (MAbs) are currently the major class of protein bio therapeutic being developed by biotechnology and pharmaceutical companies. Monoclonal Antibodies discusses the challenges and issues revolving around development of a monoclonal antibody produced by recombinant DNA technology into a therapeutic agent.This book covers downstream processing which includes design of processes to manufacture the formulation, formulation design, fill and finish into closure systems and routes of administration. The characterization of the final drug product is covered where the use... View Details
Process Scale Purification of Antibodies
by Uwe Gottschalk (Editor)
Traditional column chromatography dominates current purification technology, and many of the productivity gains that have been achieved have relied on upscaling such devices. However, this comes with a cost penalty and the pharmaceutical industry has reached the point at which further upscaling becomes economically unsupportable. This book offers a broad-based reassessment of old and new purification methods, incorporating an analysis of innovative new trends in purification. The book has wide coverage of different antibody purification strategies and brings together top-tier experts to... View Details
Process Scale Purification of Antibodies
by Uwe Gottschalk (Editor)
Promoting a continued and much-needed renaissance in biopharmaceutical manufacturing, this book covers the different strategies and assembles top-tier technology experts to address the challenges of antibody purification.
• Updates existing topics and adds new ones that include purification of antibodies produced in novel production systems, novel separation technologies, novel antibody formats and alternative scaffolds, and strategies for ton-scale manufacturing
• Presents new and updated discussions of different purification technologies, focusing on how they... View Details
Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry (Woodhead Publishing Series in Biomedicine)
by William R Strohl (Author), Lila M Strohl (Author)
The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in... View Details
Monoclonal Antibodies: Methods and Protocols (Methods in Molecular Biology)
by Vincent Ossipow (Editor), Nicolas Fischer (Editor)
Monoclonal Antibodies: Methods and Protocols, Second Edition expands upon the previous edition with current, detailed modern approaches to isolate and characterize monoclonal antibodies against carefully selected epitopes. This edition includes new chapters covering the key steps to generate high quality monoclonals via different methods, from antigen generation to epitope mapping and quality control of the purified IgG. Chapters are divided into four parts corresponding to four distinct objectives. Part I covers monoclonal antibody generation, Part II deals with monoclonal... View Details
Therapeutic Monoclonal Antibodies: From Bench to Clinic
by Zhiqiang An (Editor)
70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. First book to address the discovery and development of antibody therapeutics in their entirety. Most chapters contain experimental data to illustrate the principles described in them. Authors provide detailed methodologies that readers can take away with them and use in their own laboratories. View Details